Rheumnow Podcast

STEP Talks from RNL26 Part #2

STEP: Obesity and Inflammation: Weight management in Rheumatology. Dr. Uzma Haque 
STEP: Mitigating Risk for Rheumatic Disease Patients Undergoing Orthopedic Surgery. Dr. Susan Goodman

STEP Talks from RNL26 Part #1

STEP: Disease Modification in OA - Dr. Tuhina Neogi
STEP: History of Gout  - Dr. Robert Terkeltaub

Rheumatoid Arthritis Faculty Panel Q&A

Rheumatoid Arthritis Faculty Panel Q&A

ILD in RA - Recent Advances. Dr. Jeffrey Sparks

ILD in RA - Recent Advances. Dr. Jeffrey Sparks

The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle

The Mucosal Hypothesis of Rheumatoid Arthritis.  Dr. Kristin Demoruelle

Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova

Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau?  Dr. Elena Myasoedova

Poets Know It (3.13.2026)

Dr. Jack Cush reviews the news, regulatory decisions and new journal articles.

UBER Rheumatology Ride (3.6.2026)

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com

Early Decisions and Impact: Risankizumab in Bio-Naive Patients With PsA Sponsored by AbbVie Medical Affairs + Health Impact

DERM on RheumNow PODCAST (February 2026)

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.
 Features Dr. Jack Cush, Editor at RheumNow.com. 

SHOW NOTES
FDA sent a complete response letter to AstraZeneca on their application (BLA) for anifrolumabs (Saphnelo) subcutaneous use in SLE. Despite a positive TULIP-SC trial & EU approval of SC-anifrolumab, FDA & sponsor still have to work things out. CRL reasons are unknown https://t.co/3dNwEyolrj

Review of Calcinosis Cutis - Surgical intervent. most effective (excision, curettage, laser ablation, etc). Medical measures inconsistently, partially effective, best if used early & localized (CCB, TCN, probenecid, immunomodulation, biologics, colchicine, NA thiosulfate, & JAKi https://t.co/rv0hQBv6nX

Systematic Review of Targeted Rx for Systemic Sclerosis: from 32 RCTs & 2036 pts Rx w/ 23 targeted agents. Guselkumab had greatest effect on mRSS, followed by tofacitinib, inebilizumab, & baricitinib. For FVC, B-cell Rx (belimumab, RTX) had highest efficacy https://buff.ly/vHOSRws

Dermatomyositis outcomes w/ 2475 pts (claims) & 1196 pts (EHR). Half had myositis panels & 35% had + MSAbs. Steroid use common in 69% & 74%. HCQ, MTX, MMF. Outocmes (per 1000PYs) wereL all-cause hospitalisation 92, malignancy 15.3, ILD 6.4, and myocarditis 2.1 https://t.co/DJqKGNGX76
Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb

Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27)   https://t.co/1REWmod73W

Together PSO Trial - Combination Ixekizumab and Tirzepatide Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over https://t.co/YWCjN2NyGM